Biosimilar On Hold: Sandoz’s Zarxio Launch Delayed Indefinitely
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal appeals court blocks filgrastim-sndz from reaching market pending resolution of Neupogen maker Amgen’s appeal over ‘patent dance.’